In this open-label, international, multicenter, controlled platform randomized clinical trial of critically ill patients hospitalized for COVID-19, P2Y12 inhibitors did not significantly improve the composite of survival to hospital discharge or the number of days free of cardiovascular or respiratory organ support. The gene discussed is P2RY12; the disease is COVID-19.